Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States.
Journal: Journal of medical economics
Published: June 11, 2025
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS.
Journal: European journal of case reports in internal medicine
Published: January 15, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial.
Journal: HemaSphere
Published: September 19, 2022
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Journal: Drugs of today (Barcelona, Spain : 1998)
Published: August 19, 2022
Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report.
Journal: Transplantation proceedings
Published: September 30, 2021
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Journal: British journal of haematology
Published: August 04, 2021
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 09, 2020
Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition.
Journal: NPJ genomic medicine
Published: September 16, 2020
Melflufen for relapsed and refractory multiple myeloma.
Journal: Expert opinion on investigational drugs
Published: September 14, 2020
Exercise, cancer and cardiovascular disease: what should clinicians advise?
Journal: Cardiovascular endocrinology & metabolism
Published: May 17, 2020
Trends in the use of therapeutic plasma exchange in multiple myeloma.
Journal: Journal of clinical apheresis
Published: March 13, 2020
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Journal: Investigational new drugs
Published: February 12, 2020
Last Updated: 09/26/2026